You are here

P&T® Journal contents for May 2007

Features

Commentary
Although several years have passed since health savings accounts became available to Americans, the number of enrollees has remained relatively low. This article explores some of the pitfalls of the plans and the reluctance of the public to climb aboard.
Miriam Reisman
P&T Around the world
The authors present an update to an earlier P&T article on the embargo of Priorix measles–mumps–rubella vaccine after a deadly health scare in Ho Chi Minh City.
Peter Teichman, MD, and Nguyen Tri Doan, MD
The author discusses the procedures, safeguards, and costs involved when less expensive agents replace preferred drugs in the same pharmacological class.
Robert P. Rapp, PharmD, FCCP
The authors describe the changes in the prescribing patterns for NSAIDs that resulted when valdecoxib (Bextra) and rofecoxib (Vioxx) were withdrawn from the market.
Molly T. Vogt, PhD, Bethany Fedutes-Henderson, PharmD, Amit Duggal, PharmD, MPH, Nicole T. Ansani, PharmD, John Gillespie, MD, and Terence Starz, MD
Book Review
Author: Robert L. Shook
Reviewed by Burton Orland, BS, RPh
Sitagliptin/metformin (Janumet) for diabetes, lapatinib (Tykerb) for HER-2–positive breast cancer, and protein C concentrate powder (Ceprotin) for venous disorders are reviewed.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial
David Nash, MD, MBA, reports on the results of a BlueCross BlueShield survey on how consumers use the Internet to obtain information about medical treatments.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains the potential problems that can result when new medication protocols are implemented too quickly.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses forthcoming changes to two laws calling for pediatric drug-testing trials.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
Dr. Paris Abrams and Dr. Nino Marzella review dabigatran (Rendix), a direct thrombin inhibitor.
Paris Abrams, PharmD, and Nino Marzella, BS, PharmD